Filter posts

Developments in the creation of a single EU Patent System stalled – Again.

By Catherine McLoughlin, specialist solicitor for Biotech and Pharmaceutical Companies, Pannone LLP After 40 years …

The U.S. Government’s Position in ACLU v. Myriad Genetics

Hans Sauer, BIO’s Deputy General Counsel for Intellectual Property, comments on  the Department of Justice’s brief …

Patent Evergreening in India: Response from the Other Side

Thank you Adriana for commenting on my article Patent “Ever-Greening”: Novartis Confronts Patent Myth in …

Seed Patents: How Innovation May Get Lost in the Grain Elevator

The Bowman v. Monsanto case currently on petition for a writ of certiorari to the …

Prior User Rights and Trade Secrets

By Joe Allen, President, Allen and Associates One theme of the day is the cloud …

Recent Developments in Patentability: Prometheus and Myriad

By Joe Allen, President, Allen and Associates Recent Developments in Patentability: Prometheus and Myriad at …

From Bench to Bedside in a Bioeconomy

By Joe Allen, President, Allen and Associates It’s a sign of a well crafted program …

Measuring the Impact of Innovation

By Joe Allen, President, Allen and Associates It’s always an indication of interest and importance …

Gene Patent Discussion Should Include Industrial, Environmental, & Ag Biotech

Twenty-three industrial and agricultural biotech companies, ranging from development-stage businesses to all of the largest …

2012 BIO International Convention: Academic and Tech Transfer Community

Universities have historically been on the front lines of translating innovative research into novel medicines …